+1 347 708 0418
Disease-Modifying Antirheumatic Drug market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Disease-Modifying Antirheumatic Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Non-Steroidal Anti-Inflammatory Drugs
Steroidal Anti-Inflammatory Drugs
Slow Acting Drug
Immunological Preparation
Segment by Application
Pharmaceutical Industry
Hospital and Clinic
Other
By Company
AbbVie
Amgen
Pfizer
Roche Holding AG
Novartis International AG
Johnson & Johnson
Bristol-Myers Squibb
Merck
UCB S.A.
Eli Lilly and Company
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
1 Study Coverage
1.1 Disease-Modifying Antirheumatic Drug Product Introduction
1.2 Market by Type
1.2.1 Global Disease-Modifying Antirheumatic Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Non-Steroidal Anti-Inflammatory Drugs
1.2.3 Steroidal Anti-Inflammatory Drugs
1.2.4 Slow Acting Drug
1.2.5 Immunological Preparation
1.3 Market by Application
1.3.1 Global Disease-Modifying Antirheumatic Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Pharmaceutical Industry
1.3.3 Hospital and Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Disease-Modifying Antirheumatic Drug Sales Estimates and Forecasts 2017-2028
2.2 Global Disease-Modifying Antirheumatic Drug Revenue Estimates and Forecasts 2017-2028
2.3 Global Disease-Modifying Antirheumatic Drug Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Disease-Modifying Antirheumatic Drug Sales by Region
2.4.1 Global Disease-Modifying Antirheumatic Drug Sales by Region (2017-2022)
2.4.2 Global Sales Disease-Modifying Antirheumatic Drug by Region (2023-2028)
2.5 Global Disease-Modifying Antirheumatic Drug Revenue by Region
2.5.1 Global Disease-Modifying Antirheumatic Drug Revenue by Region (2017-2022)
2.5.2 Global Disease-Modifying Antirheumatic Drug Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Disease-Modifying Antirheumatic Drug Sales by Manufacturers
3.1.1 Global Top Disease-Modifying Antirheumatic Drug Manufacturers by Sales (2017-2022)
3.1.2 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Disease-Modifying Antirheumatic Drug in 2021
3.2 Global Disease-Modifying Antirheumatic Drug Revenue by Manufacturers
3.2.1 Global Disease-Modifying Antirheumatic Drug Revenue by Manufacturers (2017-2022)
3.2.2 Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Disease-Modifying Antirheumatic Drug Revenue in 2021
3.3 Global Disease-Modifying Antirheumatic Drug Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Disease-Modifying Antirheumatic Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Disease-Modifying Antirheumatic Drug Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Disease-Modifying Antirheumatic Drug Sales by Type
4.1.1 Global Disease-Modifying Antirheumatic Drug Historical Sales by Type (2017-2022)
4.1.2 Global Disease-Modifying Antirheumatic Drug Forecasted Sales by Type (2023-2028)
4.1.3 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2017-2028)
4.2 Global Disease-Modifying Antirheumatic Drug Revenue by Type
4.2.1 Global Disease-Modifying Antirheumatic Drug Historical Revenue by Type (2017-2022)
4.2.2 Global Disease-Modifying Antirheumatic Drug Forecasted Revenue by Type (2023-2028)
4.2.3 Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Type (2017-2028)
4.3 Global Disease-Modifying Antirheumatic Drug Price by Type
4.3.1 Global Disease-Modifying Antirheumatic Drug Price by Type (2017-2022)
4.3.2 Global Disease-Modifying Antirheumatic Drug Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Disease-Modifying Antirheumatic Drug Sales by Application
5.1.1 Global Disease-Modifying Antirheumatic Drug Historical Sales by Application (2017-2022)
5.1.2 Global Disease-Modifying Antirheumatic Drug Forecasted Sales by Application (2023-2028)
5.1.3 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2017-2028)
5.2 Global Disease-Modifying Antirheumatic Drug Revenue by Application
5.2.1 Global Disease-Modifying Antirheumatic Drug Historical Revenue by Application (2017-2022)
5.2.2 Global Disease-Modifying Antirheumatic Drug Forecasted Revenue by Application (2023-2028)
5.2.3 Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Application (2017-2028)
5.3 Global Disease-Modifying Antirheumatic Drug Price by Application
5.3.1 Global Disease-Modifying Antirheumatic Drug Price by Application (2017-2022)
5.3.2 Global Disease-Modifying Antirheumatic Drug Price Forecast by Application (2023-2028)
6 North America
6.1 North America Disease-Modifying Antirheumatic Drug Market Size by Type
6.1.1 North America Disease-Modifying Antirheumatic Drug Sales by Type (2017-2028)
6.1.2 North America Disease-Modifying Antirheumatic Drug Revenue by Type (2017-2028)
6.2 North America Disease-Modifying Antirheumatic Drug Market Size by Application
6.2.1 North America Disease-Modifying Antirheumatic Drug Sales by Application (2017-2028)
6.2.2 North America Disease-Modifying Antirheumatic Drug Revenue by Application (2017-2028)
6.3 North America Disease-Modifying Antirheumatic Drug Market Size by Country
6.3.1 North America Disease-Modifying Antirheumatic Drug Sales by Country (2017-2028)
6.3.2 North America Disease-Modifying Antirheumatic Drug Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Disease-Modifying Antirheumatic Drug Market Size by Type
7.1.1 Europe Disease-Modifying Antirheumatic Drug Sales by Type (2017-2028)
7.1.2 Europe Disease-Modifying Antirheumatic Drug Revenue by Type (2017-2028)
7.2 Europe Disease-Modifying Antirheumatic Drug Market Size by Application
7.2.1 Europe Disease-Modifying Antirheumatic Drug Sales by Application (2017-2028)
7.2.2 Europe Disease-Modifying Antirheumatic Drug Revenue by Application (2017-2028)
7.3 Europe Disease-Modifying Antirheumatic Drug Market Size by Country
7.3.1 Europe Disease-Modifying Antirheumatic Drug Sales by Country (2017-2028)
7.3.2 Europe Disease-Modifying Antirheumatic Drug Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Disease-Modifying Antirheumatic Drug Market Size by Type
8.1.1 Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Type (2017-2028)
8.1.2 Asia Pacific Disease-Modifying Antirheumatic Drug Revenue by Type (2017-2028)
8.2 Asia Pacific Disease-Modifying Antirheumatic Drug Market Size by Application
8.2.1 Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Application (2017-2028)
8.2.2 Asia Pacific Disease-Modifying Antirheumatic Drug Revenue by Application (2017-2028)
8.3 Asia Pacific Disease-Modifying Antirheumatic Drug Market Size by Region
8.3.1 Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Region (2017-2028)
8.3.2 Asia Pacific Disease-Modifying Antirheumatic Drug Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Disease-Modifying Antirheumatic Drug Market Size by Type
9.1.1 Latin America Disease-Modifying Antirheumatic Drug Sales by Type (2017-2028)
9.1.2 Latin America Disease-Modifying Antirheumatic Drug Revenue by Type (2017-2028)
9.2 Latin America Disease-Modifying Antirheumatic Drug Market Size by Application
9.2.1 Latin America Disease-Modifying Antirheumatic Drug Sales by Application (2017-2028)
9.2.2 Latin America Disease-Modifying Antirheumatic Drug Revenue by Application (2017-2028)
9.3 Latin America Disease-Modifying Antirheumatic Drug Market Size by Country
9.3.1 Latin America Disease-Modifying Antirheumatic Drug Sales by Country (2017-2028)
9.3.2 Latin America Disease-Modifying Antirheumatic Drug Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Disease-Modifying Antirheumatic Drug Market Size by Type
10.1.1 Middle East and Africa Disease-Modifying Antirheumatic Drug Sales by Type (2017-2028)
10.1.2 Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue by Type (2017-2028)
10.2 Middle East and Africa Disease-Modifying Antirheumatic Drug Market Size by Application
10.2.1 Middle East and Africa Disease-Modifying Antirheumatic Drug Sales by Application (2017-2028)
10.2.2 Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue by Application (2017-2028)
10.3 Middle East and Africa Disease-Modifying Antirheumatic Drug Market Size by Country
10.3.1 Middle East and Africa Disease-Modifying Antirheumatic Drug Sales by Country (2017-2028)
10.3.2 Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 AbbVie
11.1.1 AbbVie Corporation Information
11.1.2 AbbVie Overview
11.1.3 AbbVie Disease-Modifying Antirheumatic Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 AbbVie Disease-Modifying Antirheumatic Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 AbbVie Recent Developments
11.2 Amgen
11.2.1 Amgen Corporation Information
11.2.2 Amgen Overview
11.2.3 Amgen Disease-Modifying Antirheumatic Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Amgen Disease-Modifying Antirheumatic Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Amgen Recent Developments
11.3 Pfizer
11.3.1 Pfizer Corporation Information
11.3.2 Pfizer Overview
11.3.3 Pfizer Disease-Modifying Antirheumatic Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Pfizer Disease-Modifying Antirheumatic Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Pfizer Recent Developments
11.4 Roche Holding AG
11.4.1 Roche Holding AG Corporation Information
11.4.2 Roche Holding AG Overview
11.4.3 Roche Holding AG Disease-Modifying Antirheumatic Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Roche Holding AG Disease-Modifying Antirheumatic Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Roche Holding AG Recent Developments
11.5 Novartis International AG
11.5.1 Novartis International AG Corporation Information
11.5.2 Novartis International AG Overview
11.5.3 Novartis International AG Disease-Modifying Antirheumatic Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Novartis International AG Disease-Modifying Antirheumatic Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Novartis International AG Recent Developments
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Corporation Information
11.6.2 Johnson & Johnson Overview
11.6.3 Johnson & Johnson Disease-Modifying Antirheumatic Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Johnson & Johnson Disease-Modifying Antirheumatic Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Johnson & Johnson Recent Developments
11.7 Bristol-Myers Squibb
11.7.1 Bristol-Myers Squibb Corporation Information
11.7.2 Bristol-Myers Squibb Overview
11.7.3 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Bristol-Myers Squibb Recent Developments
11.8 Merck
11.8.1 Merck Corporation Information
11.8.2 Merck Overview
11.8.3 Merck Disease-Modifying Antirheumatic Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Merck Disease-Modifying Antirheumatic Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Merck Recent Developments
11.9 UCB S.A.
11.9.1 UCB S.A. Corporation Information
11.9.2 UCB S.A. Overview
11.9.3 UCB S.A. Disease-Modifying Antirheumatic Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 UCB S.A. Disease-Modifying Antirheumatic Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 UCB S.A. Recent Developments
11.10 Eli Lilly and Company
11.10.1 Eli Lilly and Company Corporation Information
11.10.2 Eli Lilly and Company Overview
11.10.3 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Eli Lilly and Company Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Disease-Modifying Antirheumatic Drug Industry Chain Analysis
12.2 Disease-Modifying Antirheumatic Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Disease-Modifying Antirheumatic Drug Production Mode & Process
12.4 Disease-Modifying Antirheumatic Drug Sales and Marketing
12.4.1 Disease-Modifying Antirheumatic Drug Sales Channels
12.4.2 Disease-Modifying Antirheumatic Drug Distributors
12.5 Disease-Modifying Antirheumatic Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Disease-Modifying Antirheumatic Drug Industry Trends
13.2 Disease-Modifying Antirheumatic Drug Market Drivers
13.3 Disease-Modifying Antirheumatic Drug Market Challenges
13.4 Disease-Modifying Antirheumatic Drug Market Restraints
14 Key Findings in The Global Disease-Modifying Antirheumatic Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Disease-Modifying Antirheumatic Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Non-Steroidal Anti-Inflammatory Drugs
Table 3. Major Manufacturers of Steroidal Anti-Inflammatory Drugs
Table 4. Major Manufacturers of Slow Acting Drug
Table 5. Major Manufacturers of Immunological Preparation
Table 6. Global Disease-Modifying Antirheumatic Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Disease-Modifying Antirheumatic Drug Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global Disease-Modifying Antirheumatic Drug Sales by Region (2017-2022) & (MT)
Table 9. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2017-2022)
Table 10. Global Disease-Modifying Antirheumatic Drug Sales by Region (2023-2028) & (MT)
Table 11. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2023-2028)
Table 12. Global Disease-Modifying Antirheumatic Drug Revenue by Region (2017-2022) & (US$ Million)
Table 13. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Region (2017-2022)
Table 14. Global Disease-Modifying Antirheumatic Drug Revenue by Region (2023-2028) & (US$ Million)
Table 15. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Region (2023-2028)
Table 16. Global Disease-Modifying Antirheumatic Drug Sales by Manufacturers (2017-2022) & (MT)
Table 17. Global Disease-Modifying Antirheumatic Drug Sales Share by Manufacturers (2017-2022)
Table 18. Global Disease-Modifying Antirheumatic Drug Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 19. Global Disease-Modifying Antirheumatic Drug Revenue Share by Manufacturers (2017-2022)
Table 20. Disease-Modifying Antirheumatic Drug Price by Manufacturers (2017-2022) &(USD/MT)
Table 21. Global Disease-Modifying Antirheumatic Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Disease-Modifying Antirheumatic Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Disease-Modifying Antirheumatic Drug as of 2021)
Table 23. Disease-Modifying Antirheumatic Drug Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Disease-Modifying Antirheumatic Drug Product Offered
Table 25. Date of Manufacturers Enter into Disease-Modifying Antirheumatic Drug Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Disease-Modifying Antirheumatic Drug Sales by Type (2017-2022) & (MT)
Table 28. Global Disease-Modifying Antirheumatic Drug Sales by Type (2023-2028) & (MT)
Table 29. Global Disease-Modifying Antirheumatic Drug Sales Share by Type (2017-2022)
Table 30. Global Disease-Modifying Antirheumatic Drug Sales Share by Type (2023-2028)
Table 31. Global Disease-Modifying Antirheumatic Drug Revenue by Type (2017-2022) & (US$ Million)
Table 32. Global Disease-Modifying Antirheumatic Drug Revenue by Type (2023-2028) & (US$ Million)
Table 33. Global Disease-Modifying Antirheumatic Drug Revenue Share by Type (2017-2022)
Table 34. Global Disease-Modifying Antirheumatic Drug Revenue Share by Type (2023-2028)
Table 35. Disease-Modifying Antirheumatic Drug Price by Type (2017-2022) & (USD/MT)
Table 36. Global Disease-Modifying Antirheumatic Drug Price Forecast by Type (2023-2028) & (USD/MT)
Table 37. Global Disease-Modifying Antirheumatic Drug Sales by Application (2017-2022) & (MT)
Table 38. Global Disease-Modifying Antirheumatic Drug Sales by Application (2023-2028) & (MT)
Table 39. Global Disease-Modifying Antirheumatic Drug Sales Share by Application (2017-2022)
Table 40. Global Disease-Modifying Antirheumatic Drug Sales Share by Application (2023-2028)
Table 41. Global Disease-Modifying Antirheumatic Drug Revenue by Application (2017-2022) & (US$ Million)
Table 42. Global Disease-Modifying Antirheumatic Drug Revenue by Application (2023-2028) & (US$ Million)
Table 43. Global Disease-Modifying Antirheumatic Drug Revenue Share by Application (2017-2022)
Table 44. Global Disease-Modifying Antirheumatic Drug Revenue Share by Application (2023-2028)
Table 45. Disease-Modifying Antirheumatic Drug Price by Application (2017-2022) & (USD/MT)
Table 46. Global Disease-Modifying Antirheumatic Drug Price Forecast by Application (2023-2028) & (USD/MT)
Table 47. North America Disease-Modifying Antirheumatic Drug Sales by Type (2017-2022) & (MT)
Table 48. North America Disease-Modifying Antirheumatic Drug Sales by Type (2023-2028) & (MT)
Table 49. North America Disease-Modifying Antirheumatic Drug Revenue by Type (2017-2022) & (US$ Million)
Table 50. North America Disease-Modifying Antirheumatic Drug Revenue by Type (2023-2028) & (US$ Million)
Table 51. North America Disease-Modifying Antirheumatic Drug Sales by Application (2017-2022) & (MT)
Table 52. North America Disease-Modifying Antirheumatic Drug Sales by Application (2023-2028) & (MT)
Table 53. North America Disease-Modifying Antirheumatic Drug Revenue by Application (2017-2022) & (US$ Million)
Table 54. North America Disease-Modifying Antirheumatic Drug Revenue by Application (2023-2028) & (US$ Million)
Table 55. North America Disease-Modifying Antirheumatic Drug Sales by Country (2017-2022) & (MT)
Table 56. North America Disease-Modifying Antirheumatic Drug Sales by Country (2023-2028) & (MT)
Table 57. North America Disease-Modifying Antirheumatic Drug Revenue by Country (2017-2022) & (US$ Million)
Table 58. North America Disease-Modifying Antirheumatic Drug Revenue by Country (2023-2028) & (US$ Million)
Table 59. Europe Disease-Modifying Antirheumatic Drug Sales by Type (2017-2022) & (MT)
Table 60. Europe Disease-Modifying Antirheumatic Drug Sales by Type (2023-2028) & (MT)
Table 61. Europe Disease-Modifying Antirheumatic Drug Revenue by Type (2017-2022) & (US$ Million)
Table 62. Europe Disease-Modifying Antirheumatic Drug Revenue by Type (2023-2028) & (US$ Million)
Table 63. Europe Disease-Modifying Antirheumatic Drug Sales by Application (2017-2022) & (MT)
Table 64. Europe Disease-Modifying Antirheumatic Drug Sales by Application (2023-2028) & (MT)
Table 65. Europe Disease-Modifying Antirheumatic Drug Revenue by Application (2017-2022) & (US$ Million)
Table 66. Europe Disease-Modifying Antirheumatic Drug Revenue by Application (2023-2028) & (US$ Million)
Table 67. Europe Disease-Modifying Antirheumatic Drug Sales by Country (2017-2022) & (MT)
Table 68. Europe Disease-Modifying Antirheumatic Drug Sales by Country (2023-2028) & (MT)
Table 69. Europe Disease-Modifying Antirheumatic Drug Revenue by Country (2017-2022) & (US$ Million)
Table 70. Europe Disease-Modifying Antirheumatic Drug Revenue by Country (2023-2028) & (US$ Million)
Table 71. Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Type (2017-2022) & (MT)
Table 72. Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Type (2023-2028) & (MT)
Table 73. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue by Type (2017-2022) & (US$ Million)
Table 74. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue by Type (2023-2028) & (US$ Million)
Table 75. Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Application (2017-2022) & (MT)
Table 76. Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Application (2023-2028) & (MT)
Table 77. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue by Application (2017-2022) & (US$ Million)
Table 78. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue by Application (2023-2028) & (US$ Million)
Table 79. Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Region (2017-2022) & (MT)
Table 80. Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Region (2023-2028) & (MT)
Table 81. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue by Region (2017-2022) & (US$ Million)
Table 82. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue by Region (2023-2028) & (US$ Million)
Table 83. Latin America Disease-Modifying Antirheumatic Drug Sales by Type (2017-2022) & (MT)
Table 84. Latin America Disease-Modifying Antirheumatic Drug Sales by Type (2023-2028) & (MT)
Table 85. Latin America Disease-Modifying Antirheumatic Drug Revenue by Type (2017-2022) & (US$ Million)
Table 86. Latin America Disease-Modifying Antirheumatic Drug Revenue by Type (2023-2028) & (US$ Million)
Table 87. Latin America Disease-Modifying Antirheumatic Drug Sales by Application (2017-2022) & (MT)
Table 88. Latin America Disease-Modifying Antirheumatic Drug Sales by Application (2023-2028) & (MT)
Table 89. Latin America Disease-Modifying Antirheumatic Drug Revenue by Application (2017-2022) & (US$ Million)
Table 90. Latin America Disease-Modifying Antirheumatic Drug Revenue by Application (2023-2028) & (US$ Million)
Table 91. Latin America Disease-Modifying Antirheumatic Drug Sales by Country (2017-2022) & (MT)
Table 92. Latin America Disease-Modifying Antirheumatic Drug Sales by Country (2023-2028) & (MT)
Table 93. Latin America Disease-Modifying Antirheumatic Drug Revenue by Country (2017-2022) & (US$ Million)
Table 94. Latin America Disease-Modifying Antirheumatic Drug Revenue by Country (2023-2028) & (US$ Million)
Table 95. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales by Type (2017-2022) & (MT)
Table 96. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales by Type (2023-2028) & (MT)
Table 97. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue by Type (2017-2022) & (US$ Million)
Table 98. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue by Type (2023-2028) & (US$ Million)
Table 99. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales by Application (2017-2022) & (MT)
Table 100. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales by Application (2023-2028) & (MT)
Table 101. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue by Application (2017-2022) & (US$ Million)
Table 102. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue by Application (2023-2028) & (US$ Million)
Table 103. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales by Country (2017-2022) & (MT)
Table 104. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales by Country (2023-2028) & (MT)
Table 105. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue by Country (2017-2022) & (US$ Million)
Table 106. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue by Country (2023-2028) & (US$ Million)
Table 107. AbbVie Corporation Information
Table 108. AbbVie Description and Major Businesses
Table 109. AbbVie Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 110. AbbVie Disease-Modifying Antirheumatic Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. AbbVie Recent Developments
Table 112. Amgen Corporation Information
Table 113. Amgen Description and Major Businesses
Table 114. Amgen Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 115. Amgen Disease-Modifying Antirheumatic Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Amgen Recent Developments
Table 117. Pfizer Corporation Information
Table 118. Pfizer Description and Major Businesses
Table 119. Pfizer Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 120. Pfizer Disease-Modifying Antirheumatic Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Pfizer Recent Developments
Table 122. Roche Holding AG Corporation Information
Table 123. Roche Holding AG Description and Major Businesses
Table 124. Roche Holding AG Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 125. Roche Holding AG Disease-Modifying Antirheumatic Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Roche Holding AG Recent Developments
Table 127. Novartis International AG Corporation Information
Table 128. Novartis International AG Description and Major Businesses
Table 129. Novartis International AG Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 130. Novartis International AG Disease-Modifying Antirheumatic Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Novartis International AG Recent Developments
Table 132. Johnson & Johnson Corporation Information
Table 133. Johnson & Johnson Description and Major Businesses
Table 134. Johnson & Johnson Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 135. Johnson & Johnson Disease-Modifying Antirheumatic Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Johnson & Johnson Recent Developments
Table 137. Bristol-Myers Squibb Corporation Information
Table 138. Bristol-Myers Squibb Description and Major Businesses
Table 139. Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 140. Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Bristol-Myers Squibb Recent Developments
Table 142. Merck Corporation Information
Table 143. Merck Description and Major Businesses
Table 144. Merck Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 145. Merck Disease-Modifying Antirheumatic Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Merck Recent Developments
Table 147. UCB S.A. Corporation Information
Table 148. UCB S.A. Description and Major Businesses
Table 149. UCB S.A. Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 150. UCB S.A. Disease-Modifying Antirheumatic Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. UCB S.A. Recent Developments
Table 152. Eli Lilly and Company Corporation Information
Table 153. Eli Lilly and Company Description and Major Businesses
Table 154. Eli Lilly and Company Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 155. Eli Lilly and Company Disease-Modifying Antirheumatic Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Eli Lilly and Company Recent Developments
Table 157. Key Raw Materials Lists
Table 158. Raw Materials Key Suppliers Lists
Table 159. Disease-Modifying Antirheumatic Drug Distributors List
Table 160. Disease-Modifying Antirheumatic Drug Customers List
Table 161. Disease-Modifying Antirheumatic Drug Market Trends
Table 162. Disease-Modifying Antirheumatic Drug Market Drivers
Table 163. Disease-Modifying Antirheumatic Drug Market Challenges
Table 164. Disease-Modifying Antirheumatic Drug Market Restraints
Table 165. Research Programs/Design for This Report
Table 166. Key Data Information from Secondary Sources
Table 167. Key Data Information from Primary Sources
List of Figures
Figure 1. Disease-Modifying Antirheumatic Drug Product Picture
Figure 3. Global Disease-Modifying Antirheumatic Drug Market Share by Type in 2021 & 2028
Figure 3. Non-Steroidal Anti-Inflammatory Drugs Product Picture
Figure 4. Steroidal Anti-Inflammatory Drugs Product Picture
Figure 5. Slow Acting Drug Product Picture
Figure 6. Immunological Preparation Product Picture
Figure 7. Global Disease-Modifying Antirheumatic Drug Market Share by Application in 2021 & 2028
Figure 8. Pharmaceutical Industry
Figure 9. Hospital and Clinic
Figure 10. Other
Figure 11. Disease-Modifying Antirheumatic Drug Report Years Considered
Figure 12. Global Disease-Modifying Antirheumatic Drug Sales 2017-2028 (MT)
Figure 13. Global Disease-Modifying Antirheumatic Drug Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Disease-Modifying Antirheumatic Drug Revenue 2017-2028 (US$ Million)
Figure 15. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 16. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2017-2022)
Figure 17. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2023-2028)
Figure 18. North America Disease-Modifying Antirheumatic Drug Sales YoY (2017-2028) & (MT)
Figure 19. North America Disease-Modifying Antirheumatic Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 20. Europe Disease-Modifying Antirheumatic Drug Sales YoY (2017-2028) & (MT)
Figure 21. Europe Disease-Modifying Antirheumatic Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 22. Asia-Pacific Disease-Modifying Antirheumatic Drug Sales YoY (2017-2028) & (MT)
Figure 23. Asia-Pacific Disease-Modifying Antirheumatic Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 24. Latin America Disease-Modifying Antirheumatic Drug Sales YoY (2017-2028) & (MT)
Figure 25. Latin America Disease-Modifying Antirheumatic Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 26. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales YoY (2017-2028) & (MT)
Figure 27. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 28. The Disease-Modifying Antirheumatic Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 29. The Top 5 and 10 Largest Manufacturers of Disease-Modifying Antirheumatic Drug in the World: Market Share by Disease-Modifying Antirheumatic Drug Revenue in 2021
Figure 30. Global Disease-Modifying Antirheumatic Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 31. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2017-2028)
Figure 32. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Type (2017-2028)
Figure 33. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2017-2028)
Figure 34. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Application (2017-2028)
Figure 35. North America Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2017-2028)
Figure 36. North America Disease-Modifying Antirheumatic Drug Revenue Market Share by Type (2017-2028)
Figure 37. North America Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2017-2028)
Figure 38. North America Disease-Modifying Antirheumatic Drug Revenue Market Share by Application (2017-2028)
Figure 39. North America Disease-Modifying Antirheumatic Drug Sales Share by Country (2017-2028)
Figure 40. North America Disease-Modifying Antirheumatic Drug Revenue Share by Country (2017-2028)
Figure 41. U.S. Disease-Modifying Antirheumatic Drug Revenue (2017-2028) & (US$ Million)
Figure 42. Canada Disease-Modifying Antirheumatic Drug Revenue (2017-2028) & (US$ Million)
Figure 43. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2017-2028)
Figure 44. Europe Disease-Modifying Antirheumatic Drug Revenue Market Share by Type (2017-2028)
Figure 45. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2017-2028)
Figure 46. Europe Disease-Modifying Antirheumatic Drug Revenue Market Share by Application (2017-2028)
Figure 47. Europe Disease-Modifying Antirheumatic Drug Sales Share by Country (2017-2028)
Figure 48. Europe Disease-Modifying Antirheumatic Drug Revenue Share by Country (2017-2028)
Figure 49. Germany Disease-Modifying Antirheumatic Drug Revenue (2017-2028) & (US$ Million)
Figure 50. France Disease-Modifying Antirheumatic Drug Revenue (2017-2028) & (US$ Million)
Figure 51. U.K. Disease-Modifying Antirheumatic Drug Revenue (2017-2028) & (US$ Million)
Figure 52. Italy Disease-Modifying Antirheumatic Drug Revenue (2017-2028) & (US$ Million)
Figure 53. Russia Disease-Modifying Antirheumatic Drug Revenue (2017-2028) & (US$ Million)
Figure 54. Asia Pacific Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2017-2028)
Figure 55. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue Market Share by Type (2017-2028)
Figure 56. Asia Pacific Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2017-2028)
Figure 57. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue Market Share by Application (2017-2028)
Figure 58. Asia Pacific Disease-Modifying Antirheumatic Drug Sales Share by Region (2017-2028)
Figure 59. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue Share by Region (2017-2028)
Figure 60. China Disease-Modifying Antirheumatic Drug Revenue (2017-2028) & (US$ Million)
Figure 61. Japan Disease-Modifying Antirheumatic Drug Revenue (2017-2028) & (US$ Million)
Figure 62. South Korea Disease-Modifying Antirheumatic Drug Revenue (2017-2028) & (US$ Million)
Figure 63. India Disease-Modifying Antirheumatic Drug Revenue (2017-2028) & (US$ Million)
Figure 64. Australia Disease-Modifying Antirheumatic Drug Revenue (2017-2028) & (US$ Million)
Figure 65. Taiwan Disease-Modifying Antirheumatic Drug Revenue (2017-2028) & (US$ Million)
Figure 66. Indonesia Disease-Modifying Antirheumatic Drug Revenue (2017-2028) & (US$ Million)
Figure 67. Thailand Disease-Modifying Antirheumatic Drug Revenue (2017-2028) & (US$ Million)
Figure 68. Malaysia Disease-Modifying Antirheumatic Drug Revenue (2017-2028) & (US$ Million)
Figure 69. Philippines Disease-Modifying Antirheumatic Drug Revenue (2017-2028) & (US$ Million)
Figure 70. Latin America Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2017-2028)
Figure 71. Latin America Disease-Modifying Antirheumatic Drug Revenue Market Share by Type (2017-2028)
Figure 72. Latin America Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2017-2028)
Figure 73. Latin America Disease-Modifying Antirheumatic Drug Revenue Market Share by Application (2017-2028)
Figure 74. Latin America Disease-Modifying Antirheumatic Drug Sales Share by Country (2017-2028)
Figure 75. Latin America Disease-Modifying Antirheumatic Drug Revenue Share by Country (2017-2028)
Figure 76. Mexico Disease-Modifying Antirheumatic Drug Revenue (2017-2028) & (US$ Million)
Figure 77. Brazil Disease-Modifying Antirheumatic Drug Revenue (2017-2028) & (US$ Million)
Figure 78. Argentina Disease-Modifying Antirheumatic Drug Revenue (2017-2028) & (US$ Million)
Figure 79. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2017-2028)
Figure 80. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue Market Share by Type (2017-2028)
Figure 81. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2017-2028)
Figure 82. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue Market Share by Application (2017-2028)
Figure 83. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales Share by Country (2017-2028)
Figure 84. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue Share by Country (2017-2028)
Figure 85. Turkey Disease-Modifying Antirheumatic Drug Revenue (2017-2028) & (US$ Million)
Figure 86. Saudi Arabia Disease-Modifying Antirheumatic Drug Revenue (2017-2028) & (US$ Million)
Figure 87. U.A.E Disease-Modifying Antirheumatic Drug Revenue (2017-2028) & (US$ Million)
Figure 88. Disease-Modifying Antirheumatic Drug Value Chain
Figure 89. Disease-Modifying Antirheumatic Drug Production Process
Figure 90. Channels of Distribution
Figure 91. Distributors Profiles
Figure 92. Bottom-up and Top-down Approaches for This Report
Figure 93. Data Triangulation
Figure 94. Key Executives Interviewed
Buy
